Company intelligence / Profile preview

NewBiologix

Epalinges, Vaud, Switzerland

Ownership: Private
Development stage: Preclinical

Overview

NewBiologix has launched advanced engineered cell lines and analytical platforms to improve the manufacturing of rAAV vectors used in gene therapies. Their technology aims to increase yield, purity, stability, and reproducibility while reducing costs. No direct clinical results as they are a technology/platform provider rather than a therapeutic developer.

Therapeutic areas: OtherRare Diseases
Modalities: Recombinant adeno-associated virus (rAAV) vectorsGene therapy platforms/cell lines
Industry: Non-Drug Biotech

Partnerships

Licensed Florabio’s HEK293 cell line as part of their proprietary offeringsAssembles network of expert partners in gene/cell therapy field

Beyond the preview

Go deeper on NewBiologix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NewBiologix.

Explore the full profile